• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
+49 (0) 69 / 606 278 – 0
[email protected]
Contact form
Patent- & Rechtsanwaltskanzlei

Patent- & Rechtsanwaltskanzlei

  • Deutsch

+49 (0) 69 / 606 278 – 0

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • xing
  • Email
MENUMENU
  • Services
    • Advice On Protective IP Rights
    • Patent Application /TM Registration
    • Enforcement Of IP Rights
    • Defence Against IP Rights Enforcement
    • Costs
  • Company
    • Fields of Law
      • Patent Law
      • Utility Model Law
      • Employees‘ Inventions
      • Trademark Law
      • Design Law
      • Trademark and Product Piracy
      • Expert Opinions
    • Our Law Firm
      • Dr. Karl-Hermann Meyer-Dulheuer
      • Dr. Tim Meyer-Dulheuer
      • Dr. Klaus Zimmermann
      • Zhichao Ying
      • Dr. Christoph Hölscher
    • Commitment
  • Contact
    • Where To Find Us
    • Write us!
    • Request call back
  • Blog

Overview: These Major Pharmaceuticals lose Patent Protection in 2017

16. January 2017

A Pharmaceutical Drug Patent can be worth billions and can be responsible to secure the success of a company. That’s why manufactures are eager to protect them as soon as possible. But since Patents can only be protected for a maximum of 20 years, sooner or later a patent is about to expire. Approximately 22 drug patents will lose their protection. An infographic will give you a good overview including numbers and names!

Pharmaceuticals_Patent_Expiration_2017

Approving Pharmaceutical Patents take a lot of time. It’s a process that requires paperwork, approvals, exemptions and more – not just in your own company but also before governmental institutions.

In 2017, a total of 22 drug patents will lose protection according to Dickson’s calculations. That happens to exactly match the number of new drugs approved in 2016, a more than 50 percent decrease on approvals the year before.

To be more precise: Mainly Merck, Novartis and Bristol-Myers Squibb are in the hot seat. Merck will lose Patent Protection for four major drugs (Invanz, Vytorin, Cancidas and Cubicin) generating a combined annual revenue of 3.8 billion US-Dollars. That’s 10% of Merck’s annual sales of 2015!

 

Infographic by DICKSON – Major Drug Patents to expire in 2017

Last Thursday DICKSON released its 2017 infographic showing which (major) drug patents are about to expire in 2017. It gives detailed insights about the drugs, their annual revenue and general informations about patenting drugs:

Going-off Pharmaceutical Patents in 2017
Click to Enlarge // Source: DICKSON

 

Patenting Pharmaceutical Patents – we help you!

Our patent attorneys come from several countries and some of them are specialized in Chemistry and Biology. We know of what you are speaking. Let’s not lose any more time and agree on a joint telephone call. You can request a free call-back without any obligations at:

 

Sources:

Infographic: DICKSON

Text: DICKSON Blog Article and FAQ of the U.S. Food and Drug Administration

Cover-Photo: By stevepb at Pixabay (CC0 Public Domain)

  • share  
  • share 
  • share 
  • tweet 
  • share 

Category iconPatent Law

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

More articles about: Patent Law

All articles

Blog Menu

  • Design Law
  • Healthcare & Lifesciences
  • International Intellectual Property
  • Licenses
  • News from our law firm
  • Overall
  • Patent Law
  • Product- and Trademark piracy
  • Trademark Law

Recent Posts

  • BPatG: Patent claim of cancer drug on active substance as salt 7. March 2022
  • Grant for European IP Protection: SME Fund 2022 4. March 2022
  • CODE-X vs. Cody’s: Likelihood of confusion in drinks? 25. February 2022
  • EOS lip balm no 3D trademark – appeal before ECJ not admissible 24. February 2022

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Das könnte Sie auch interessieren:

4. March 2022
Grant for European IP Protection: SME Fund 2022

Grant for European IP Protection: SME Fund 2022

22. February 2022
PAP is in force: UPC possible in 2022

PAP is in force: UPC possible in 2022

8. February 2022
Germany: Value in dispute and costs in proceedings

Germany: Value in dispute and costs in proceedings

3. February 2022
PCT application – does the principle of joint applicants apply?

PCT application – does the principle of joint applicants apply?

1. February 2022
Proof of patent infringement by whistleblower

Proof of patent infringement by whistleblower

19. January 2022
Computer Data identification declared invalid

Computer Data identification declared invalid

Contact us or request a call back

+49 (0) 69 / 606 278 – 0
[email protected]
Request a call back

Footer

Contact

Hanauer Landstrasse 287
D – 60314 Frankfurt am Main
Deutschland
+49 (0) 69 / 606 278 – 0
+49 (0) 69 / 606 278 – 199
[email protected]

Office Hours
Moday – Friday:   08:00-18:00

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Law Firm

  • Request non-binding call back
  • Company
  • Our Law Firm
  • ISO Certificate
  • Privacy Policy
  • Data handling for clients
  • Imprint

Follow Us

  • Facebook
  • Twitter
  • LinkedIn
  • xing
  • Email

Newsletter Signup

© Patent- & Rechtsanwaltskanzlei Meyer-Dulheuer MD Legal Patentanwälte PartG mbB

Contact Form

 

Give us a call, send us an email or fill out the contact form.

+49 (0) 69 / 606 278 – 0
[email protected]

Kontaktformular

 

Rufen Sie uns an, schicken Sie uns eine Mail oder füllen Sie das Kontaktformular aus.

+49 (0) 69 / 606 278 – 0
[email protected]